82 related articles for article (PubMed ID: 19947562)
1. [Factors influencing the progression-free survival time of prostate cancer patients after endocrine therapy].
Guan YB; Zhang YF; Wen H; Zhou SQ; Dai YT
Zhonghua Nan Ke Xue; 2009 Sep; 15(9):801-5. PubMed ID: 19947562
[TBL] [Abstract][Full Text] [Related]
2. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
4. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
5. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
6. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
7. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
[TBL] [Abstract][Full Text] [Related]
8. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
9. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
Lerner SE; Blute ML; Bergstralh EJ; Bostwick DG; Eickholt JT; Zincke H
J Urol; 1996 Jul; 156(1):137-43. PubMed ID: 8648775
[TBL] [Abstract][Full Text] [Related]
11. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
14. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
15. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
16. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
17. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy and prognostic factors.
du Fossé W; Billiet I; Mattelaer J
Acta Urol Belg; 1997 Oct; 65(3):53-62. PubMed ID: 9421937
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
20. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]